SMC Ltd. Expands Drug Delivery Capabilities with Oval Medical Technologies Acquisition
[button link=”http://www.ovalmedical.com/wp-content/uploads/2016/12/SMCLtd_Oval_121316v3.pdf” bg_color=”#40b4e5″ window=”yes”]Download PDF[/button]
Somerset, Wisconsin – SMC Ltd., a global contract manufacturer of pharmaceutical and finished medical devices, announced today that it has acquired Oval Medical Technologies Ltd., a specialty pharmaceutical device company developing next generation autoinjectors based in Cambridge, UK.
Oval’s autoinjector platforms address the unmet needs in the self-injection market utilizing both cyclic olefin plastic and glass primary drug containers. Their autoinjectors deliver both non-viscous and viscous drugs. The convenient design of the autoinjector provides patients with an ease-of-use solution for fast and simple two-step administration in emergency and non-emergency environments. This unique platform is available to pharmaceutical companies for their drug delivery systems.
SMC’s global healthcare contract manufacturing expertise enables SMC and Oval to become a comprehensive combination product solution provider for the pharmaceutical industry.
“We are excited to have Oval Medical Technologies within the SMC family. SMC’s years of experience in medical device contract manufacturing paired with Oval’s innovative approach to drug delivery combination products creates a complete solution for the pharmaceutical market. In addition to autoinjectors, the Oval team brings a wealth of knowledge and experience in the design, development and manufacturing of inhalation products,” said Chetan N. Patel, President and Founder, SMC Ltd.
“Pharmaceutical companies require reliable customized devices for their high value biologics. As part of SMC, Oval will be well placed to provide customers with devices that meet their needs and those of their patients. The combination of Oval’s design and development capability and SMC’s capabilities in global manufacturing, will ensure a high level of reliability in product performance and a fast route to market. These capabilities are also important for the acceleration of the development of our innovative Epinephrine combination product. This small innovative, and reliable design is favored by patients who need to carry these potentially lifesaving products at all times,” said Barbara Lead, Chief Executive Officer, Oval Medical Technologies.
“SMC, as one of the leading global contract manufacturers of medical devices, gives Oval a fantastic opportunity to support our customers seamlessly from concept to full-scale industrialization, and provide class-leading quality and time-to-market. SMC and Oval have a deep range of capabilities and experience, which will benefit not only our pharmaceutical customers, but the patients and others who ultimately use these products,” said Matthew Young, Founder and Chief Technology Officer, Oval Medical Technologies.
About SMC Ltd.
SMC Ltd. provides global contract manufacturing solutions of single-use devices for the pharmaceutical, medical and diagnostics industries. With 700,000 square feet dedicated to healthcare manufacturing, SMC provides full product services from initial concept through the final packaged device; including: program management, design and development, product manufacturing, clinical manufacturing, electronics integration, and global supply chain management. www.smcltd.com
About Oval Medical
Founded in 2009 by Matthew Young, Oval has developed unique technology platforms providing customised autoinjectors for delivery of up to 3 ml of drug formulations with viscosities up to 100 centipoise, in small, user-friendly devices. Devices can also be developed for the delivery of formulations with much higher viscosities. Oval’s radical approach to the delivery of emergency drugs has enabled the design of an epinephrine autoinjector that is intuitive to use in a crisis and small enough to be carried discretely in a pocket. www.ovalmedical.com
For More Information:
+44 1223 437140